Delhi lab selected for human clinical trials of Covaxin

By: |
Published: July 23, 2020 2:15 AM

Dr Dangs Lab has started receiving 50 to 100 samples per day from various trial sites for safety testing. It plans to scale up operations to cover 12 sites across the country during this month as per assigned timelines.

The clinical trial is randomised, double-blind and placebo-controlled.The clinical trial is randomised, double-blind and placebo-controlled.

A private laboratory in New Delhi has been selected as the central laboratory for human clinical trials of Covaxin, India’s indigenous Covid-19 vaccine, being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

Dr Dangs Lab has started receiving 50 to 100 samples per day from various trial sites for safety testing. It plans to scale up operations to cover 12 sites across the country during this month as per assigned timelines.

The clinical trial is randomised, double-blind and placebo-controlled.

Dr Dangs Lab is currently processing all samples for screening and safety for the various phases of this clinical trial, whereas all the efficacy studies will be performed in NIV-Pune.

Stringent quality norms driven by good clinical laboratory practice are being followed as mandated by regulatory authorities. Experts at the lab are working collectively to provide timely results to fulfil the need of an effective Covid-19 vaccine.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Bihar reports highest single-day spike of 4,071 COVID-19 cases; 15 more fatalities push death toll to 465
2Centre asks states to not get ‘overawed’ by rise in daily Covid cases, test aggressively
3Covid vaccine panel to discuss procurement, logistics and priority groups on Wednesday